The collaboration also expands Avalanche’s reach across Asia and the Middle East, where Animoca Brands brings deep market access and ecosystem leadership.Read more: https://t.co/uDjYWoYb9O ...

NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Sitka Gold Corporation (TSX-V: SIG; OTCQX: SITKF), a Canadian based mining exploration company, has qualified to trade on the OTCQX® Best Market. Sitka Gold Corporation upgraded to OTCQX from the OTCQB® Venture Market. Sitka Gold Corporation begins trading today on OTCQX under the symbol “SITKF.” U.S. investors can find current ...

Summary of Insmed Fireside Chat at TD Cowen Healthcare Conference Company Overview - **Company**: Insmed - **Key Product**: BRINSUPRI, a treatment for bronchiectasis Key Industry Insights - **Market Dynamics**: The bronchiectasis market is currently underserved, with Insmed targeting 250,000 patients diagnosed with two or more exacerbations, which could lead to peak sales exceeding $5 billion [27][28][65] - **Patient Experience**: Positive patient experiences with BRINSUPRI are crucial for driving repeat prescriptions from physicians. Anecdotal evidence suggests significant improvements in patients' quality of life [25][26][40] Financial Performance - **Q4 Revenue**: Insmed reported Q4 revenue of $144 million, significantly exceeding both buy-side and sell-side consensus estimates [6][7] - **Future Projections**: Initial revenue guidance for the upcoming quarters has been revised upwards, with estimates now exceeding $1 billion, driven by strong physician engagement and patient feedback [34][37][40] Launch Strategy - **Physician Engagement**: Insmed has engaged over 4,000 physicians, with a focus on expanding the breadth and depth of prescribing behavior. Half of these physicians have only written one prescription, indicating potential for growth as they receive positive feedback from patients [7][8][40][42] - **Market Access**: Insmed is working with insurance companies to streamline access for patients, particularly those with two or more exacerbations. The company has offered modest discounts to facilitate policy shaping [50][61] Competitive Landscape - **ARIKAYCE**: Insmed has been selling ARIKAYCE for eight years, which has a challenging administration process. In contrast, BRINSUPRI is a once-daily pill with a favorable safety profile, making it easier to prescribe [23][24] - **TPIP Development**: Insmed is developing TPIP, a once-daily inhaled treatment for pulmonary arterial hypertension (PAH). The competitive landscape is evolving, but Insmed believes TPIP's profile remains strong against emerging products [66][67] Regulatory and Market Challenges - **MFN Policy**: Insmed is monitoring the Most Favored Nation (MFN) policy, which could impact pricing strategies in the U.S. market. The company is cautious but optimistic about navigating these regulatory challenges [46][48] - **Insurance Coverage**: The company is addressing payer access and reimbursement hurdles, with a focus on simplifying the attestation process for patients with two or more exacerbations [50][51] Research and Development - **ENCORE Study**: The upcoming ENCORE study for ARIKAYCE could significantly increase the addressable market, potentially doubling the current target population [82][86] - **Patient Outcomes**: Insmed is focused on demonstrating durable culture conversion in patients, which is critical for gaining physician trust and expanding usage [97][98] Conclusion - Insmed is positioned for growth with BRINSUPRI, leveraging positive patient experiences and strong physician engagement. The company is navigating market access challenges while preparing for significant upcoming studies that could expand its market presence.

Washington and Taipei have finalized a trade deal to cut tariffs and to boost market access for US products in Asia. Goods from Taiwan will now face a 15% tariff, with some exceptions for tech and pharmaceuticals. Taiwan is pledging to buy $44 billion of U.S. energy and further open its markets.But uncertainty remains over Taipei's promises to invest hundreds of billions in U.S. chipmaking. Let's bring in Bloomberg Washington Deputy Bureau Chief Laura Davison. Laura, so we now have this finalization of a tr ...

Industry Overview - The Zacks Oil and Gas - Exploration and Production - Canadian industry is heavily influenced by oil and gas prices, which directly affect cash flow, spending plans, and investor confidence [1][2] - The industry faces challenges such as prolonged price weakness, infrastructure issues, and regulatory uncertainty, leading to production delays and inconsistent results [1][5] - Despite these challenges, improved market access, better pipeline utilization, and stricter capital discipline have helped stabilize margins and reduce pricing discounts [1][4] Current Market Conditions - The industry currently holds a Zacks Industry Rank of 232, placing it in the bottom 3% of 243 Zacks industries, indicating bearish near-term prospects [6][8] - Analysts have revised earnings estimates for the industry down by 22% for 2026 over the past year, reflecting a negative outlook for earnings growth potential [8] Performance Metrics - Over the past year, the industry has increased by 8.9%, outperforming the broader Zacks Oil - Energy Sector's 3.3% increase but lagging behind the S&P 500's 19.3% rise [10] Valuation - The industry is currently trading at a trailing 12-month EV/EBITDA ratio of 5.37, significantly lower than the S&P 500's 18.94 and slightly below the sector's 5.62 [14] Key Companies Canadian Natural Resources (CNQ) - Canadian Natural is one of the largest independent energy producers in Canada, with a diversified portfolio and a market capitalization of around $72 billion [17][19] - The company focuses on maximizing free cash flow and shareholder returns, maintaining financial flexibility across commodity cycles [18] InPlay Oil (IPOOF) - InPlay Oil is a Canadian light-oil producer with a market capitalization of around $272 million, producing about 18,500 barrels of oil equivalent per day [22][24] - The company emphasizes capital discipline and has a Zacks Consensus Estimate indicating 300% year-over-year growth in 2026 earnings per share [24] Gran Tierra Energy (GTE) - Gran Tierra Energy operates in Colombia, Ecuador, and Canada, controlling over 2.7 million gross acres and producing roughly 46,600 barrels of oil equivalent per day [27][28] - The company has a market capitalization of around $175 million and a Zacks Consensus Estimate indicating 28.1% growth in 2026 earnings [29]

Summary of BridgeBio Pharma FY Conference Call Company Overview - **Company**: BridgeBio Pharma (NasdaqGS:BBIO) - **Key Product**: Attruby, a treatment for ATTR-CM (transthyretin amyloid cardiomyopathy) - **Market Context**: The company has seen a stock price increase of approximately 160% year-to-date, outperforming the XBI index which increased by 30% [1] Core Insights and Arguments Attruby Launch and Market Share - **Launch Success**: The launch of Attruby is described as going extremely well, with the company achieving a market share in the first-line treatment setting now well into the 20% range, with a long-term goal of 30-40% [2][3] - **Clinical Data**: Attruby is noted for having near-complete clinical data on its label, including a 50% reduction in hospitalization at 30 months and a 42% reduction in all-cause mortality and hospitalization [3] - **Market Access Initiatives**: The company has implemented a 28-day free trial program and offers extensive support through patient access liaisons and reimbursement managers, facilitating easier access to Attruby [4] Q4 Expectations and Market Dynamics - **Q4 Performance**: The company anticipates a strong performance in Q4, despite having three fewer selling weeks compared to other quarters. The discontinuation of Pfizer's Vyndaqel is expected to be more beneficial in 2026 rather than Q4 [6][8] - **Switching Patients**: The company aims to convert patients from Vyndaqel to Attruby, particularly in accounts where Vyndaqel was previously used [9][10] Competitive Landscape - **Competitor Actions**: Pfizer's introduction of a similar free trial program for Vyndamax is acknowledged, but the company believes that clinical differentiation will maintain its competitive edge [11][12] - **Diagnosis Rates**: The diagnosis of ATTR-CM is still considered underdiagnosed, with significant room for growth. The number of PYP scans has grown at a CAGR of about 30% since 2019 [13][14] Future Market Opportunities - **Generic Competition**: The potential entry of generics for Vyndaqel in 2028 is discussed, but the company emphasizes that Attruby's clinical differentiation will sustain its market position [16][18] - **Achondroplasia Market**: The company is preparing for the launch of infigratinib for achondroplasia, positioning it as a potential first oral treatment targeting the FGFR3 mutation [19][21] Pricing Strategy - **Pricing Considerations**: The company plans to price new products in accordance with their opportunity size, with potential pricing for rare diseases ranging from $400,000 to $900,000 [38][39] Additional Important Points - **Regulatory Filings**: The company expects to file NDAs for Encaleret and BBP-418 in the first half of next year, with launches anticipated in Q4 2026 and Q1 2027 [36] - **Safety and Efficacy**: The company aims to maintain low rates of hyperphosphatemia in patients treated with infigratinib, with a target of no more than 20% experiencing low-grade hyperphosphatemia [28] This summary encapsulates the key points discussed during the conference call, highlighting BridgeBio Pharma's strategic positioning, market dynamics, and future outlook.

Regulatory Approval - Polymarket received CFTC approval for an amended designation, paving the way for intermediated U.S market access [1]

Regulatory Approval - Polymarket receives CFTC approval of amended order of designation, enabling intermediated U S market access [1] Market Access - Polymarket获得美国商品期货交易委员会（CFTC）的修订令批准，从而能够进入美国市场 [1]

Market Access - ASX opens access to the US real estate market [1] - ASX's unique capability might be its superpower in providing this access [1]

Economic Impact - America has significantly benefited from international market access, exemplified by the global presence of American brands like McDonald's and Hollywood movies [1] - The American Empire's common market has encompassed the entire world for the last 30 years, contributing to its prosperity [2] Geopolitical Strategy - America's expansion occurred through Manifest Destiny, acquisitions like the Philippines and Puerto Rico, and extending its influence globally after 1945 and 1991 [1] Globalism Concerns - There are concerns that "International Capitalism" is akin to Globalism, which some believe has negatively impacted the West, particularly the US [2]